On June 14, the U.S. Food and Drug Administration (FDA) approved Menhibrix, a combination vaccine for infants and children ages 6 weeks through 18 months, for prevention of invasive disease caused by Neisseria meningitidis serogroups C and Yand Haemophilus influenzae type b. Read more Read more.
FDA approves new combination vaccine for children
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
